Fig. 2From: Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational studyLongitudinal measurements of RVESV over 18 months. There were significant changes in RVESV over time (p < 0.001). By Sidak-adjusted pairwise comparisons with the baseline, the mean RVESV showed a small but significant increase at 6 and 12 months (both p < 0.001), that was no longer significant at 18 months (p = 0.14). Data shown as mean and 95% confidence intervals (vertical bars)Back to article page